New York, NY · Founded 2021 · Privately Held (backing)
Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. Helex is based in New York, NY and was founded in 2021. Its last reported valuation was $36.9 million in Oct 2025. It has raised $6.6 million.
Last reported valuation
$36.9M
Oct 2026
Priced at
—
Total raised
$6.6M
Last round
—
No prints on record
No secondary trades in Helex shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Helex with a free account
·Watch Helex: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Helex stock.
